Making a case for using γδ T cells against SARS-CoV-2.
Crit Rev Microbiol
; 46(6): 689-702, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-1730391
ABSTRACT
Intensive worldwide efforts are underway to determine both the pathogenesis of SARS-CoV-2 infection and the immune responses in COVID-19 patients in order to develop effective therapeutics and vaccines. One type of cell that may contribute to these immune responses is the γδ T lymphocyte, which plays a key role in immunosurveillance of the mucosal and epithelial barriers by rapidly responding to pathogens. Although found in low numbers in blood, γδ T cells consist the majority of tissue-resident T cells and participate in the front line of the host immune defense. Previous studies have demonstrated the critical protective role of γδ T cells in immune responses to other respiratory viruses, including SARS-CoV-1. However, no studies have profoundly investigated these cells in COVID-19 patients to date. γδ T cells can be safely expanded in vivo using existing inexpensive FDA-approved drugs such as bisphosphonate, in order to test its protective immune response to SARS-CoV-2. To support this line of research, we review insights gained from previous coronavirus research, along with recent findings, discussing the potential role of γδ T cells in controlling SARS-CoV-2. We conclude by proposing several strategies to enhance γδ T cell's antiviral function, which may be used in developing therapies for COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
T-Lymphocyte Subsets
/
Coronavirus Infections
/
Betacoronavirus
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Crit Rev Microbiol
Journal subject:
Microbiology
Year:
2020
Document Type:
Article
Affiliation country:
1040841X.2020.1822279
Similar
MEDLINE
...
LILACS
LIS